Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 11-12, 2004, Pages 1381-1386

  Gardner, J D ^a   Sloan, S ^b   Robinson, M ^c   Miner Jr , P B ^c  

^a Science for Organizations Inc   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ACIDITY; ARTICLE; CONTROLLED STUDY; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HISTOGRAM; HUMAN; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY; PH MEASUREMENT; POSTPRANDIAL STATE; PRIORITY JOURNAL; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CIRCADIAN RHYTHM; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; OMEPRAZOLE; POSTPRANDIAL PERIOD; PROTON PUMPS; RANDOM ALLOCATION; REFERENCE VALUES; STOMACH;

EID: 11144291432     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02279.x     Document Type: Article

References (16)

1. Merki HS, Witzel L, Walt RP, et al. Day-to-day variation of 24-hour intragastric acidity. Gastroenterology 1988; 94: 887-91.
2. Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 1992; 51: 59-67.
3. Bruley des Varannes S, Levy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche JP. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8: 309-14.
4. Bell NJV, Hunt RH. Time to maximum effect of lansoprazole on gastric pH in normal male volunteers. Aliment Pharmacol Ther 1996; 10: 897-904.
5. Gardner JD, Sloan S, Robinson M, Miner PB. Jr. Esophageal pH has a power-law distribution in control and GERD subjects. Aliment Pharmacol Ther (in press).
6. Gardner JD, Sloan S, Miner PB, Jr, Robinson M. Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003; 17: 945-53.
7. Gardner JD, Rodriguez-Stanley S, Robinson M. Integrated acidity and the pathophysiology of GERD. Am J Gastroenterol 2001; 96: 1363-70.
8. Gardner JD, Perdomo C, Sloan S, et al. Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther 2002; 16: 455-64.
9. Motulsky H. Multiple comparisons. In: Intuitive Biostatistics. New York: Oxford university Press, 1995: 118-26.
10. Gardner JD, Gallo-Torres H, Sloan S, Robinson M, Miner PB Jr. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. Aliment Pharmacol Ther 2003, 18: 891-905.
11. Kromer W, Horbach S, Luhmann R. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology 1999; 59: 57-77.
12. Sifrim D, Holloway R, Silny J, Tack J, Lerut A, Janssens J. Composition of the postprandial refluxate in patients with gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 647-55.
13. Kawamura O, Aslam M, Rittman T, Hofmann C, Shaker R. Physical and pH properties of gastroesophagopharyngeal refluxate: a 24-hour simultaneous ambulatory impedance and pH monitoring study. Am J Gastroenterol 2004; 99: 1000-10.
14. Tutuian R, Castell DO. Combined multichannel intraluminal impedance and manometry clarifies esophageal; function abnormalities: study in 350 patients. Am J Gastroenterol 2004; 99: 1012-22.
15. Gardner JD, Sloan S, Miner PB, Jr. Robinson M. Determination of the reduction in gastric acidity necessary to prevent pathologic esophageal reflux in GERD patients treated with a proton pump inhibitor. Aliment Pharmacol Ther 2003; 17: 955-64.
16. Fletcher J, Wirz A, Young J, Vallance R, McColl KEL. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121: 775-83.